With regards to precision medicine, this alteration is reported to confer reduced sensitivity against cetuximab or panitumumab (anti-EGFR antibodies) (Di Fiore et al., 2007; Peeters et al., 2013), which is the main treatment for metastatic CRC. The gene discussed is EGFR; the disease is colorectal carcinoma.